Back
Transcatheter heart valve interventions: where are we? Where are we going?
Journal article

Transcatheter heart valve interventions: where are we? Where are we going?

  • Prendergast BD Department of Cardiology, St Thomas' Hospital, Westminster Bridge Road, London, UK.
  • Baumgartner H Division of Adult Congenital and Valvular Heart Disease, Department of Cardiovascular Medicine, University Hospital Muenster, Muenster, Germany.
  • Delgado V Department of Cardiology, Leiden University Medical Center, Albinusdreef 2, RC Leiden, The Netherlands.
  • Gérard O GE Healthcare, Chicago, IL, USA.
  • Haude M Medical Clinic I, Städtische Kliniken Neuss, Neuss, Germany.
  • Himmelmann A Astra Zeneca R&D, Gothenburg, Sweden.
  • Iung B AP-HP, Cardiology Department, Bichat Hospital, Paris-Diderot University, Paris, France.
  • Leafstedt M Medtronic, Tolochenaz, Switzerland.
  • Lennartz J Medtronic, Tolochenaz, Switzerland.
  • Maisano F Klinik für Herz- und Gefässchirurgie, UniversitätsSpital Zürich, Zürich, Switzerland.
  • Marinelli EA Daiichi-Sankyo Europe GmbH, Munich, Germany.
  • Modine T Department of Cardiovascular Surgery, Hopital Cardiologique CHRU de Lille, Lille, France.
  • Mueller M Pfizer Inc., Berlin, Germany.
  • Redwood SR Department of Cardiology, St Thomas' Hospital, Westminster Bridge Road, London, UK.
  • Rörick O Siemens Healthineers, Erlangen, Germany.
  • Sahyoun C Philips Healthcare, Best, The Netherlands.
  • Saillant E GE Healthcare, Chicago, IL, USA.
  • Søndergaard L Department of Cardiology, The Heart Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Thoenes M Edwards Lifesciences, Nyon, Switzerland.
  • Thomitzek K Bayer AG, Berlin, Germany.
  • Tschernich M GE Healthcare, Chicago, IL, USA.
  • Vahanian A AP-HP, Cardiology Department, Bichat Hospital, Paris-Diderot University, Paris, France.
  • Wendler O Department of Cardiothoracic Surgery, King's College Hospital, London, UK.
  • Zemke EJ Siemens Healthineers, Erlangen, Germany.
  • Bax JJ Department of Cardiology, Leiden University Medical Center, Albinusdreef 2, RC Leiden, The Netherlands.
Show more…
  • 2019-01-05
Published in:
  • European heart journal. - 2019
Heart Valve Diseases
Heart Valve Prosthesis
Heart Valve Prosthesis Implantation
Heart Valves
Humans
Progression-Free Survival
Prosthesis Design
Transcatheter Aortic Valve Replacement
English Transcatheter heart valve interventions have transformed the outcomes of patients with valvular heart disease (VHD) who are unfavourable candidates for surgery. Technological advances have allowed extension of these interventions to younger or lower risk patients and those with other forms of VHD and may in the future permit earlier treatment of VHD in less symptomatic patients or those with moderate disease. The balance of risks and benefits is likely to differ between lower and higher risk patients, and more evidence is needed to evaluate the net benefit of transcatheter technology in these groups. As academic researchers, clinicians, industry, and patient stakeholders collaborate to research these broader indications for transcatheter valve interventions, it is essential to address (i) device durability and deliverability, (ii) specific anatomical needs (e.g. bicuspid aortic valves, aortic regurgitation, mitral and tricuspid valve disease), (iii) operator training, and (iv) the reinforced importance of the multidisciplinary Heart Team.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/215296
Statistics
Document views: 67 File downloads: